Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tuberculosis treatment

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    283 result(s) found for: Tuberculosis treatment. Displaying page 9 of 15.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2009-016163-12 Sponsor Protocol Number: 20090403 Start Date*: 2010-07-02
    Sponsor Name:Amgen Inc
    Full Title: A Long-term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects with Psoriasis.
    Medical condition: Moderate to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002378-30 Sponsor Protocol Number: A3921210 Start Date*: Information not available in EudraCT
    Sponsor Name:Pfizer Inc.
    Full Title: OPEN-LABEL INDUCTION AND MAINTENANCE STUDY OF ORAL CP-690,550 (TOFACITINIB) IN CHILDREN WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Medical condition: MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) SK (Completed) FR (Trial now transitioned) HU (Trial now transitioned) FI (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001733-16 Sponsor Protocol Number: A3921083 Start Date*: 2012-04-10
    Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017, USA
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTRE STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 FOR INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE C...
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004856 10011402 Crohn's disease (colon) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Prematurely Ended) ES (Completed) HU (Completed) GR (Completed) AT (Completed) CZ (Completed) NL (Completed) BG (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2007-000381-20 Sponsor Protocol Number: 27820 Start Date*: 2007-11-16
    Sponsor Name:Merck Serono S.A. - Geneva
    Full Title: A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple...
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) FR (Completed) GB (Completed) CZ (Completed) BE (Completed) EE (Completed) AT (Completed) PT (Completed) NL (Completed) DE (Completed) DK (Completed) IT (Completed) GR (Completed) LV (Completed) LT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-003123-38 Sponsor Protocol Number: RPC01-202 Start Date*: 2012-12-11
    Sponsor Name:Celgene International II Sàrl (CIS II)
    Full Title: A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL-GROUP STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF INDUCTION THERAPY WITH RPC1063 IN PATIENTS WITH MODERATELY...
    Medical condition: Moderately to severely active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) PL (Completed) SK (Completed) BG (Completed) GR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-001740-54 Sponsor Protocol Number: MK-3222-012 Start Date*: 2013-12-16
    Sponsor Name:Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc.
    Full Title: A 28-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 900222 / MK-3222, Followed by...
    Medical condition: Moderate-to-Severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002466-39 Sponsor Protocol Number: MVD-PROT-001 Start Date*: 2019-04-17
    Sponsor Name:University Medical Center Groningen
    Full Title: Morphine or Fentanyl for Refractory dyspnea in COPD
    Medical condition: Chronic Obstructive Pulmonary Disease, COPD
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005448-87 Sponsor Protocol Number: B1801315 Start Date*: 2012-05-14
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF THE MAINTENANCE OF EFFICACY OF ETANERCEPT PLUS DMARD(S) COMPARED WITH DMARD(S) ALONE IN SUBJECTS WITH RHEUMATOID ARTHRITIS AFTER ACHIEVING AN ...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2016-004419-11 Sponsor Protocol Number: SC35 Start Date*: 2017-04-20
    Sponsor Name:Radboud university medical center
    Full Title: Safety and efficacy of interleukin-1 inhibitor anakinra for the amelioration of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic stem c...
    Medical condition: Mucositis and febrile neutropenia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004867 10028127 Mucositis LLT
    19.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002916-28 Sponsor Protocol Number: EMR200166-001 Start Date*: 2013-12-12
    Sponsor Name:Merck KGaA
    Full Title: An Open-label, One-arm, Proof of Concept Trial to Evaluate the Safety of ATX-MS-1467 (MSC2358825A) and its Effect on Immune Tolerance in Subjects with Relapsing Multiple Sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10067063 Progressive relapsing multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: View results
    EudraCT Number: 2005-001243-28 Sponsor Protocol Number: P04320 Start Date*: 2005-08-03
    Sponsor Name:essex pharma GmbH
    Full Title: Study to determine the non inferiority of GROUP I (“high need”) compared to GROUP II (“low need”) concerning the efficacy of infliximab with respect to safety and tolerability in patients suffering...
    Medical condition: Moderate to severe plaque-type psoriaris (psoriasis vulgaris).
    Disease: Version SOC Term Classification Code Term Level
    7.1 10037153 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001182-41 Sponsor Protocol Number: C0168X97 Start Date*: 2007-03-27
    Sponsor Name:Ass.Prof. Petros Sfikakis
    Full Title: Infliximab for Diabetic Macular Edema Refractory to Laser Photocoagulation: a Randomized, Double-Masked, Placebo-Controlled, Cross-over, 32 Weeks Study
    Medical condition: Diabetic Macular Oedema
    Disease: Version SOC Term Classification Code Term Level
    8.1 10057915 Diabetic macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004381-24 Sponsor Protocol Number: C87035 Start Date*: 2015-03-02
    Sponsor Name:UCB Celltech
    Full Title: A Phase 2, Open-label, Multicenter Study to Assess the Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease (NURTURE Study)
    Medical condition: Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    17.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-000176-15 Sponsor Protocol Number: IZN-101 Start Date*: 2018-06-19
    Sponsor Name:Izana Bioscience Limited
    Full Title: A phase 2a proof of concept, randomised, double-blind, placebo-controlled study to evaluate the safety/tolerability and efficacy of 4 subcutaneous injections of namilumab (150 mg) given over 10 wee...
    Medical condition: moderate-to-severe axial spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10071400 Axial spondyloarthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002322-73 Sponsor Protocol Number: I4V-MC-JADV Start Date*: 2013-01-14
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo- and Active Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients with Moderately to Severely Active Rheumatoid Arthritis Who H...
    Medical condition: Moderately to severely active rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GR (Completed) BE (Completed) LV (Completed) GB (Prematurely Ended) DE (Completed) PT (Completed) CZ (Completed) NL (Completed) LT (Completed) SK (Completed) ES (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2016-000570-37 Sponsor Protocol Number: GS-US-417-0303 Start Date*: 2016-11-29
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Randomized, Double-blind, Placebo-and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination with Methotr...
    Medical condition: Moderately to severely active rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) GB (Completed) HU (Completed) DE (Completed) CZ (Completed) ES (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-011720-59 Sponsor Protocol Number: PsA001 Start Date*: 2010-04-22
    Sponsor Name:SCHWARZ BIOSCIENCES, GmbH, A Member of the UCB Group of Companies
    Full Title: PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH ADULT ONSET ACTIVE AND PROGRESSIV...
    Medical condition: Psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Completed) GB (Completed) BE (Completed) HU (Completed) NL (Completed) CZ (Completed) IE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000665-30 Sponsor Protocol Number: CHS-0214-05 Start Date*: 2015-07-30
    Sponsor Name:Coherus BioSciences, Inc.
    Full Title: An Open-Label Safety Extension Study (OLSES) Evaluating the Long term Safety and Durability of Response of CHS 0214 (CHS 0214-05)
    Medical condition: Rheumatoid arthritis Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10042952 Systemic rheumatoid arthritis LLT
    18.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000566-40 Sponsor Protocol Number: Protocol H7U-MC-IDAH Start Date*: 2005-08-18
    Sponsor Name:Eli Lilly Company
    Full Title: A Pivotal Long-Term, Open-Label, Parallel Study of the Efficacy and Safety of Human Insulin Inhalation Powder in Patients with Type 1 Diabetes Mellitus
    Medical condition: Patients with type 1 diabetes mellitus and many patients with type 2 diabetes mellitus require daily use of insulin for the maintenance of normal glucose homeostasis. At present, insulin can be de...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-000300-42 Sponsor Protocol Number: 03AR0298 Start Date*: 2013-01-18
    Sponsor Name:National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
    Full Title: A long-term outcome study with the IL-1 receptor antagonist Anakinra/Kineret® in patients with Neonatal onset multisystem inflammatory disease (Nomid/Cinca syndrome)
    Medical condition: neonatal onset multisystem inflammatory disease (NOMID/CINCA)
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 15 07:03:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA